Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
February 29, 2024 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and...
Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
February 28, 2024 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., and ALBANY, Ga., and WASHINGTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), together with The Mended Hearts, Inc. and WomenHeart: The...
Cytokinetics Reports Fourth Quarter 2023 Financial Results
February 27, 2024 16:00 ET
|
Cytokinetics, Incorporated
Topline Results from SEQUOIA-HCM Announced in DecemberShowed Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint and Improvements in All Secondary Endpoints ...
Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
February 13, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at...
Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
January 29, 2024 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its sixth annual Communications Grant Program, intended to...
Cytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
January 25, 2024 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure,...
Cytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
January 18, 2024 13:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation at CMR 2024 taking place online and in person in...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 29, 2023 it granted stock options to purchase an aggregate...
Cytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...